Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2455

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622455)

This text is a package insert for Lisdexamfetamine capsules containing details about the medication, including the dosage, storage instructions, and manufacturer information. It is recommended to scan the QR code for dosage information and dispense the capsules to patients as directed. The medication should be stored within a certain temperature range and kept in a tight, light-resistant container. Remember to keep the capsules out of reach of children.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

FDA Label Image

Figure 1 (Lisdexcaps 02)

This text seems to provide information related to a special population, specifically focusing on gender (male/female), age range (65-75 years), renal impairment levels (mild, moderate, severe, end-stage renal disease), and a fold change with a confidence interval of 90%. It also mentions a change relative to reference. This data appears to be part of a research or study involving a specific population and their renal health status.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

FDA Label Image

Figure 3 (Lisdexcaps 04)

This is "Interacting drug" information regarding various medications and their interaction with different enzymes. It includes drugs like Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, and Midazolam, along with their respective enzyme substrates. The data displayed includes Pharmacokinetic parameters like Cmax and AUC and compares them with fold change and 90% CI.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

FDA Label Image

Figure 5 (Lisdexcaps 06)

FDA Label Image

Figure 6 (Lisdexcaps 07)

This information shows the LS Mean (SE) PERMP Total Scores over a period of time for Phacebo (presumably placebo) and Lisdexamfetamine. The scores are measured at different time points post-dose, with data points at 4, 8, 12, and 14 hours. The scale of the scores ranges from 250 to 330.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

This text shows the proportion of subjects with relapse/treatment failure (%) over time (days after randomization) for Lisdexamfetamine.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.